News | Heart Valve Technology | November 26, 2019| Dave Fornell, Editor

TriClip Device For Tricuspid Regurgitation Effective at One Year in TRILUMINATE Study

Preliminary results of TRILUMINATE pivotal trial shows good safety and reduction of TR in 87 percent of patients

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a technical iteration of MitraClip, was found to be safe and effective for edge-to-edge transcatheter repair of tricuspid regurgitation (TR).

The data was shared during a late-breaking session at London Valves by Professor Georg Nickenig, lead investigator of the study and chair of Internal Medicine and Polyclinic II at the University of Bonn, Germany, presented findings. Data show a TR reduction of at least one grade in 87 percent of patients with symptomatic or greater TR and improvements in quality-of-life. 

The study also found low major adverse event rates at 1 year, with no new device-related events after 30 days. There was a significant improvement in NYHA heart failure class I/II (22% to 80%), KCCQ (16.8 points) and 6-minute walk (33.1 meters) persisted at one year. 

Nickenig said at the reduction of TR was associated with significantly decreased right ventricular (RV) dimensions, suggesting positive remodeling, with significant improvement in RV function.

The proportion of subjects with moderate or less TR increased from 4 percent at baseline to 54 percent at 30 days, and 64 percent at one year, indicating a durable TR repair, Nickenig explained. 

Continued improvements in NYHA functional class from 30 days to 1-year.

The TriClip is a version of the MitraClip used for transcatheter mitral valve repair (TMVR) to resolve mitral regurgitation. A post hoc registry analysis of MitraClip use for TR has indicated TR reduction and improved clinical outcomes out to one year.[1,2,3]

 

The Current Standard of Care for Tricuspid Regurgitation 

Tricuspid regurgitation (TR) is a frequent disease with poor prognosis. Treatment for TR is currently limited to the use of diuretics and high-risk surgical procedures. Nickenig said minimally invasive catheter-based procedures (such as TriClip) may reduce TR with low procedural risk.

Investigators in the TRILUMINATE Trial include Georg Nickenig, M.D.; Marcel Weber, M.D.; Phillip Lurz, M.D.; Paul Sorajja, M.D.; Jörg Hausleiter, M.D.; Marta Sitges, M.D.; Paolo Denti, M.D.; Jean-Noël Trochu, M.D., Ph.D.; Michael Nabauer, M.D.; and Rebecca T. Hahn, M.D.

 

Related TriClip and TRILUMINATE  Content:

Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System

Abbott Tricuspid Valve Repair System Reduces Tricuspid Regurgitation at 30 Days

VIDEO: Tricuspid Valve Imaging and Interventions Developing Hand-in-hand — Interview with Rebecca Hahn, M.D.

Advances in Transcatheter Tricuspid Valve Technologies

VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System

Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial

 

References:

1. Nickenig G et al.,Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. Circulation. 2017;135(19):1802-1814.
2. Mehr M et al.,
1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation. JACC Cardiovasc Interv. 2019;12(15):1451-1461.
3. Besler C et al., Predictors of Procedural and Clinical Outcomes in Patients With Symptomatic Tricuspid Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.JACC Cardiovasc Interv. 2018;11(12):1119-1128.

 

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init